GSK
2 years ago ⋅ English ⋅ 3 min read
Newsroom
GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep in relapsed/refractory multiple myeloma

For media and investors only- Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex- Trial u... Read More
GSK
2 years ago ⋅ English ⋅ 3 min read
Newsroom
GSK announces major step towards sustainability ambitions with advancement of low carbon Ventolin programme to Phase III trials

For media and investors only- Next-generation propellant technology has the potential to reduce greenhouse gas emissions from Ventolin (salbutamol) inhaler by approximately 90%- Current... Read More
GSK
2 years ago ⋅ English ⋅ 6 min read
Newsroom
GSK receives positive CHMP opinion recommending momelotinib for myelofibrosis patients with anaemia

For media and investors only- If approved, momelotinib will become the first and only treatment in the EU specifically indicated for myelofibrosis patients with moderate to severe anaem... Read More
GSK
2 years ago ⋅ English ⋅ 4 min read
Newsroom
Strong year-to-date and Q3 performance drives upgrade to full-year guidance

For media and investors onlyFull results announcement PDFDownload the Q3 2023 results announcementQ3 2023 results announcement (PDF, 804.7KB)Broad-based execution drives further sales a... Read More
GSK
2 years ago ⋅ English ⋅ 5 min read
Newsroom
GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen

For media and investors only- GSK’s bepirovirsen both alone and in combination with nucleos(t)ide analogue therapy has shown functional cure in patients with chronic hepatitis B-... Read More
GSK
2 years ago ⋅ English ⋅ 5 min read
Newsroom
Phase III RUBY trial of Jemperli (dostarlimab) plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer

For media and investors only- Statistically significant and clinically meaningful overall survival benefit observed in the overall population in the trial- Dostarlimab plus chemotherapy... Read More